Elil Lilly and Co. says it plans to eliminate nearly 200 positions from its development workforce in what spokesperson Amy Sousa termed as a “voluntary exit program.” Employees who are electing to leave the company have been offered a compensation package. While the terms remain undisclosed to the public, employees have until later this month to make a decision.
In late January, Lilly was planning to lay off 485 employees throughout the United States in response to the failure of its Alzheimer’s drug, solanezumab, but says these job cuts are unrelated.
Lilly then plans to refocus its U.S.-based efforts around Alheimer’s disease, immunology and molecule-making capabilities.
With about 40,000 worldwide employees, the job cuts will represent less than 3 percent of Lilly’s global R&D workforce.
Read the STAT report